Acute Modulation of Toll-Like Receptors by Insulin by Ghanim, Husam et al.
Acute Modulation of Toll-Like Receptors
by Insulin
HUSAM GHANIM, PHD
PRIYA MOHANTY, MD
RUPALI DEOPURKAR, MD, PHD
CHING LING SIA, BSC
KELLY KORZENIEWSKI, BSC
SANAA ABUAYSHEH, BSC
AJAY CHAUDHURI, MD
PARESH DANDONA, MD
OBJECTIVE — Low-dose insulin infusion has been shown to exert a prompt and powerful
anti-inﬂammatory effect. Toll-like receptors (TLRs) are major determinants of the inﬂammatory
response to viral and bacterial pathogens. We have now hypothesized that low-dose insulin
infusion in obese type 2 diabetic patients suppresses TLR expression.
RESEARCH DESIGN AND METHODS — Ten type 2 diabetic patients were infused
with a low dose of insulin (2 units/h) and dextrose to maintain normoglycemia for 4 h, while
another 14 type 2 diabetic patients were infused with either dextrose or saline for 4 h and served
ascontrolsubjects.Bloodsampleswerecollectedbeforeandat2,4,and6h.TLRexpressionwas
determined in mononuclear cells (MNCs).
RESULTS — Insulin infusion signiﬁcantly suppressed TLR1, -2, -4, -7, and -9 mRNA expres-
sioninMNCswithin2hoftheinfusion,withamaximumfallat4hby249%,215%,30
8%, 28  5%, and 27  10% (P  0.05, for all), respectively, below the baseline. TLR2 protein
was suppressed by 19  7% (P  0.05) below the baseline at 4 h. The DNA binding of PU.1, a
major transcription factor regulating many TLR genes, was concomitantly suppressed by 24 
10% (P  0.05) by4hi nMNCs. There was no change in TLR expression or DNA binding by
PU.1 following dextrose or saline infusion in the control groups.
CONCLUSIONS — Insulin suppresses the expression of several TLRs at the transcriptional
level, possibly through its suppressive effect on PU.1.
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W
e have shown previously that in-
sulin exerts a prompt and pow-
erful anti-inﬂammatory effect,
including the suppression of nuclear fac-
tor-B (NFB) binding, reactive oxygen
species generation, and p47
phox expres-
sion by mononuclear cells (MNCs) (1,2)
in humans. Insulin has also been shown
to reduce the plasma concentrations of
manyproinﬂammatorymediatorsinclud-
ing C-reactive protein (CRP) and serum
amyloid A (SAA) within 24 h in patients
with acute myocardial infarction and in
patients undergoing coronary artery by-
pass surgery (3,4).
Toll-like receptors (TLRs) are a vari-
ety of pathogen pattern recognition re-
ceptors that recognize bacterial and viral
products and other pathogens (5). TLR4
recognizes endotoxin or lipopolysaccha-
ride (LPS) and may be a mediator of en-
dotoxin shock (6). TLR4 has also been
shown to play an important role in the
pathogenesis of atherosclerosis (7,8), di-
et-induced obesity, and the related insulin
resistance (9,10). TLR2 (in a heterodimeric
association with TLR1 or TLR6) recog-
nizes certain lipopeptides, peptidogly-
cans, and other lipid moieties derived
fromgram-positivebacteria(5).Recently,
TLR2 has been shown to mediate and ag-
gravate myocardial tissue injury in isch-
emia reperfusion–based experimental
animal models and that a deletion of
TLR2 is associated with a reduction in the
size of the experimental myocardial in-
farct (11). TLR2 deletion also results in
thepreservationofpostischemiccoronary
endothelial function and the prevention
of abnormal ventricular remodeling
(12,13).
TLR7 and TLR9 recognize single-
stranded viral RNA and microbial DNA,
respectively. TLR9 also modulates adap-
tiveimmuneresponsesincludingautoim-
munity against DNA and chromatin (e.g.,
systemic lupus erythematosus) (14). A
role for TLR9 and TLR2 has also been
shown in the pathogenesis of experimen-
tal type 1 diabetes, speciﬁcally related to
the autoimmune inﬂammation in the
pancreatic islet (15,16).
TranscriptionofmanyTLRsisdepen-
dent upon myeloid-speciﬁc transcription
factors including PU.1. PU.1 is a member
of the ets gene family and is a master
switch in the regulation of an array of
genes involved in myeloid cell activation
and differentiation, including TLR2, -4,
and -9 (17,18). PU.1 binds to purine-rich
regions of the TLR gene promoter to acti-
vate their transcription.
Recent data in humans have demon-
strated that TLR2 and TLR4 expression
and plasma LPS concentration are in-
creased in patients with type 2 diabetes
and that LPS concentration is related to
plasma insulin concentration and insulin
resistance (19). However, the possibility
that insulin or macronutrient intake may
modulate TLR expression has not been
investigated. In view of the recent data on
TLRinvolvementininsulinresistanceand
atherosclerosis and our previous work on
the anti-inﬂammatory effect of insulin, it
is important that the potential effects of
insulin on TLRs be investigated.
RESEARCH DESIGN AND
METHODS— Ten obese patients with
type 2 diabetes, ﬁve female and ﬁve male
subjects,wererecruitedfortheinsulininfu-
sion study (age 47.9  8.9 years, BMI
39.2  6.5 kg/m
2, and A1C 7.0  0.8%).
The subjects had well-controlled diabetes,
withaverageA1Cof70.81%.Theywere
on stable oral antidiabetes medications. All
patients were on metformin (1–2 g/day),
and six patients were on sulfonylureas
(5–10mg/dayglyburideorglipizide).None
of the subjects was on insulin or thiazoli-
denedione therapy or taking any antioxi-
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drugs. After an overnight fast, subjects
were infused with insulin (2 units/h),
with 5% glucose and 20 mEq of potas-
sium chloride for 4 h followed by2ho f
observation and wash-out. The glucose
infusion rate was titrated to maintain
blood glucose at a target level of 80–130
mg/dl. Blood glucose levels were mea-
sured every 15 min. None of the patients
had any hypoglycemic symptoms. An-
other two groups of type 2 diabetic pa-
tientswereinfusedwitheither5%glucose
(eight patients: four female and four male
subjects, aged 45.8  7.6 years, BMI
38.6  7.2 kg/m
2, and A1C 7.3  0.9%)
or normal saline (six patients: four female
and two male subjects, aged 41.5  8.2
years, BMI 36.9  6.7 kg/m
2, A1C 7.5 
1.1%) alone at a rate of 100 ml/h for 4 h
and served as control subjects. Blood
samples were collected at baseline and 2,
4, and 6 h. The protocol was approved by
the human research committee of the
State University of New York at Buffalo.
An informed consent was signed by all
subjects.
MNC isolation
Blood samples were collected in Na-
EDTA and carefully layered on lympholyte
medium (Cedarlane Laboratories,
Hornby, ON). Samples were centrifuged
and two bands separate out at the top of
the red blood cells pellet. The MNC band
was harvested and washed twice with
Hank’s balanced salt solution. This
method provides yields 95% MNC
preparation.
Quantiﬁcation of TLR (-1, -2, -4, -7,
and -9) mRNA in MNCs by RT-PCR
Total RNA was isolated using a commer-
cially available RNAqueous 4PCR Kit
(Ambion, Austin, TX). Real-time RT-PCR
was performed using Cepheid Smart Cy-
cler (Sunnyvale, CA), Sybergreen Master
Mix (Qiagen, Valencia, CA), and gene-
speciﬁc primers for TLRs (-1, -2, -4, -7,
and -9) (Life Technologies, Rockville,
MD). All values were normalized to the
expression of a group of housekeeping
genes, including actin, ubiquitin C, and
cyclophilin A.
PU.1 DNA binding activity
Nuclear PU.1 DNA binding activity was
measured by an electromobility shift as-
say. Nuclear extract was prepared from
MNCs and by high salt extraction, as de-
scribed previously (1). PU.1 assay was
performed using speciﬁc binding site oli-
gonucleotides corresponding to the PU.1
binding sites on TLR4 promoter (18):
sense CGCTTTCACTTCCTCTCAC
CCTT and antisense AAGGGTGAGAG
GAAGTGAAAGCG. The speciﬁcity of the
band was conﬁrmed by supershifting the
band with speciﬁc antibody against PU.1
(Santa Cruz Biotechnology, Santa Cruz,
CA) and by competition with cold oligo-
nucleotides. PU.1 DNA binding was ad-
justed to Oct-1 DNA binding.
Western blotting
MNC total cell lysates were prepared as
electrophoresis and immunoblotting was
carried as described before (1). Monoclo-
nal antibodies against TLR2, TLR4 (Ab-
cam, Cambridge, MA), and actin (Santa
Cruz Biotechnology) were used, and all
valueswerecorrectedforloadingtoactin.
Plasma measurements
Glucoseconcentrationsweremeasuredin
plasma by a YSI 2300 STAT Plus glucose
analyzer (Yellow Springs, OH). Enzyme-
linked immunosorbent assay was used to
measure plasma concentrations of insulin
(Diagnostic Systems Laboratories, Web-
ster,TX),monocytechemoattractantpro-
tein (MCP)-1, and soluble intercellular
adhesion molecule (sICAM)-1 (R&D Sys-
tems, Minneapolis, MN).
Statistical analysis
Statistical analysis was conducted using
SigmaStat software (SPSS, Chicago, IL).
All data are represented as means  SE.
Statisticalanalysisfrombaselineswascar-
ried out using Holm-Sidak one-way re-
peated-measures ANOVA. Dunnett’s
two-factor repeated-measures ANOVA
method was used for multiple compari-
sons between different groups.
RESULTS
Insulin and glucose concentrations
during infusions
Plasma insulin concentration increased
by166%overbaseline(from20.910.9
U/mlto50.522.4U/ml;P0.001)
during the insulin infusion, while it fell
slightly in the dextrose groups from
27.65.6U/mlto22.96.5U/mlat
4h( P  NS) and in the normal saline
group from 20.6  5.5 U/ml to 17.9 
4.7 U/ml at4h( P  NS). The mean
blood glucose concentrations changed
from12215mg/dlatbaselineto111
10 mg/dl at 4 h following insulin infu-
sion,whichwasnotsigniﬁcantlydifferent
from that observed in the control groups
(133  40 mg/dl at baseline to 125  29
mg/dl at4hi nt h edextrose group and
from13513mg/dlatbaselineto109
13 mg/dl at4hi nt h esaline group).
Suppressive effect of insulin on TLR
mRNA and protein expression in
diabetic patients
Insulin infusion suppressed the mRNA
expression of TLR1, -2, -4, -7, and -9 in
MNCs within 2 h, with a maximum fall at
4hby249%,215%,308%,28
5%, and 27  10%, respectively, below
baseline (P  0.05 for all) (Fig. 1). The
expression of mRNA for all ﬁve TLRs re-
verted to baseline 2 h after the end of the
infusion. There was no signiﬁcant change
in mRNA expression of TLR6 and TLR8
(data not shown). TLR2 protein was sup-
pressed by 19  7% below baseline at 4 h
following insulin infusion (P  0.05)
whencomparedwithbaselineandtocon-
trol subjects (Fig. 2), while TLR4 protein
levels were reduced by only 8  5% (P 
NS). There was no signiﬁcant change in
TLR expression in the control group. We
were unable to detect the other TLR pro-
teinspossiblyduetothelowerexpression
levels of these genes in the MNCs and the
relatively low sensitivity of the Western
blotting technique.
MyD88 and CD14 are essential pro-
teins involved in TLR signal transduction
and LPS binding; therefore, their expres-
sion following insulin infusion was also in-
vestigated. MyD88 and CD14 expression
was not signiﬁcantly altered following in-
sulin infusion (data not shown).
Effect of insulin infusion on PU.1
ThebindingofPU.1toaspeciﬁcandnec-
essary motif (PU-12) on the TLR4 pro-
moter in MNCs was suppressed by 24 
10%at4hfollowinginsulininfusion(P
0.05)comparedwithbaselineandcontrol
subjects(Fig.3).Thissuppressiondidnot
revert to baseline at 6 h.
Effect of insulin infusion on
proinﬂammatory mediators
Following insulin infusion, plasma con-
centrations of MCP-1 fell signiﬁcantly at
2 h and continued to fall at4hb y1 5
4% below baseline (from 270  43 ng/ml
to 228  32 ng/ml; P  0.026; repeated-
measures ANOVA). Plasma concentra-
tions of sICAM-1 were also suppressed
signiﬁcantly by 4 h following insulin in-
fusion by 10  3% below baseline (from
301  41 ng/ml to 263  24 ng/ml; P 
0.017; repeated-measures ANOVA). The
fall in MCP-1 and sICAM-1 concentra-
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compared with the control group by two-
way repeated-measures ANOVA.
CONCLUSIONS — Our data clearly
show for the ﬁrst time a potent and rapid
suppressive effect of a low dose of insulin
infusion on the expression of TLR1, -2,
-4, -7, and -9 by 20–30%, evident at 2 h,
continuing until 4 h, and reverting back
to baseline 2 h after the cessation of infu-
sion. This low-dose infusion of insulin
has previously been shown to exert a
rapidandprofoundanti-inﬂammatoryef-
fectwithin2h,asreﬂectedinthesuppres-
sion of NFB binding and an increase in
inhibitor of B expression. The fall in
TLR2 mRNA was also associated with a
reduction in the expression of TLR2 pro-
tein.Theabsenceofaclearsuppressionof
TLR4 protein level may be due to the rel-
ativelyshortperiodofinfusion.Thisissue
should be addressed in the future by
longer periods of infusion. Our data also
demonstrate clearly for the ﬁrst time that
insulin rapidly suppresses the DNA bind-
ingofPU.1toaspeciﬁcsequenceofTLR4
gene promoter. PU.1 is a key transcrip-
tion factor in the regulation of TLR tran-
scription, and, thus, its suppression is
reﬂected in the suppression of many of
TLRs to a similar extent. The pattern of
fall in TLR mRNA expression was similar
to that observed with other proinﬂamma-
tory mediators like MCP-1 and sICAM-1,
which fell at 2 h, remained low for the
duration of the infusion, and returned to
baseline at 6 h, 2 h after the cessation of
the insulin infusion. This is also consis-
tent with our previous data on the sup-
pressive effect of insulin on other indexes
Figure 1—TLR mRNA expression by RT-PCR following insulin or dextrose infusion in type 2
diabetic subjects. TLR1 (A), TLR2 (B), TLR4 (C), TLR7 (D), and TLR9 (E) mRNA expression in
MNCs of type 2 diabetic subjects following 2 units/h insulin infusion compared with dextrose and
saline infusion controls. *P  0.05, repeated-measures ANOVA compared with baseline; #P 
0.05,two-wayrepeated-measuresANOVAcomparedwithcontrolgroups.E,insulin;F,dextrose;
Œ, saline.
Figure 2—TLR2 protein expression by Western blotting following insulin, dextrose, or saline infusion in type 2 diabetes. A: Representative TLR2
immunoblot in total cell lysate from MNCs of diabetic subjects following 2 units/h insulin infusion compared with dextrose and saline infusion
controls.B:TLR2proteindensitometry.E,insulin;F,dextrose;Œ,saline.*P0.05,repeated-measuresANOVAcomparedwithbaseline;#P0.05,
two-way repeated-measures ANOVA compared with control groups.
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able consistency in the pharmacodynam-
ics of the various aspects of the anti-
inﬂammatory effects of insulin.
Recent work has shown that TLR4,
and possibly TLR2, might mediate diet-
induced obesity and insulin resistance
and might, therefore, be involved in the
pathogenesis of type 2 diabetes. It has
been shown that TLR4
/ mice are pro-
tected from high-fat diet–induced insulin
resistance (9,10). Also, RNA interference–
mediated inhibition of TLR2 expression in
muscle cells inhibited palmitate-induced
insulin resistance (20). TLR2 and TLR4
expression is increased in adipose tissue
of type 2 diabetic subjects (19) and in the
MNCs of type 1 diabetic subjects (21).
The expression of TLR4 in MNCs in type
1 diabetic subjects is related signiﬁcantly
toA1C,andtheincubationofMNCswith
glucose increases TLR4 expression (21).
LPS concentration is also higher in type 2
diabeticsubjectsandrelatedtoplasmain-
sulinconcentrationandinsulinresistance
(19).ThesefactssupportaroleoftheTLR
pathwayinthepathogenesisoftype1and
type 2 diabetes and the pathogenesis of
diabetes complications. This is consistent
with the observations that inﬂammatory
mediators interfere with insulin signaling
and might play a signiﬁcant role in the
development of insulin resistance. Thus,
the suppression of TLR4 and TLR2 ex-
pression following a low-dose insulin in-
fusion points toward a potential
suppressive role for insulin on insulin re-
sistance and atherosclerosis. Further-
more, since TLR9 is also involved in the
pathogenesis of autoimmune mecha-
nisms related to type 1 diabetes in exper-
imental animals and TLR2 is involved in
	-celldeathandthesuppressionofTLR9,
TLR2 may potentially be relevant to the
prevention of type 1 diabetes (15,16).
PU.1 is the transcription factor that
binds to a purine-rich region of the TLR
gene promoters in order to activate the
transcription of TLRs (17,18). Binding
and activation would result in increased
synthesis of TLRs at the transcriptional
level. The fact that there is a suppression
of PU.1 in parallel with the reduction in
mRNA of TLR1, -2, -4, -7, and -9 within
2 h of starting insulin infusion suggests
stronglythatthesuppressionoftranscrip-
tion of TLRs by insulin is prompt and is
probably mediated by the suppression of
this key transcription factor. This obser-
vation expands our understanding of the
anti-inﬂammatory effect of insulin.
Since TLR4 mediates the inﬂamma-
tory response to endotoxin, it is possible
thatinsulinmaypotentiallyreducethein-
ﬂammatory response to endotoxin by re-
ducing the receptor population binding
to endotoxin, provided we can demon-
strateareductioninTLR4proteinexpres-
sion with longer infusions in the future.
This effect would be in addition to the
moredirectanti-inﬂammatoryeffectofits
own through the suppression of NFB
and early growth response factor-1, two
major proinﬂammatory transcription fac-
tors. Such an additional effect may be of
considerable importance since inﬂamma-
tion triggers an increase in TLR expres-
sion and thus provides a positive
feedback for inﬂammation. This positive
feedback, which may lead to a more pro-
tracted and intense inﬂammation, would
potentially be prevented by insulin. A di-
rect anti-inﬂammatory effect of insulin
and its additional ability to suppress TLR
expression provide it a profoundly potent
combination in combating inﬂammatory
processes. The suppression of TLR2 ex-
pression at mRNA and protein level by
insulin is relevant to gram-positive bacte-
rial infections. These actions of insulin
may have contributed to the beneﬁcial ef-
fects of insulin observed by Langouche et
al.(22)inpatientsincriticalcare.Itisalso
relevant that a similar low dose of insulin
infusion causes a reduction of 40% in
plasma CRP and SAA concentrations
within 24 h in acutely ill patients with
acute myocardial infarction (3) and in pa-
tients undergoing coronary artery bypass
surgery (4). Whether a signiﬁcant part of
this suppression of CRP and SAA and the
cardioprotection observed in acute myo-
cardial infarction receives a contribution
from a reduction in TLR2 expression
needs to be carefully assessed in the
future.
Recent work (23) has shown that in
atherosclerosis, the expression of TLR1,
-2, and -4 in the arterial intima is in-
creased, especially in areas with inﬂam-
matory inﬁltration. The increase in TLR2
andTLR4expressionisassociatedwithan
increase in intranuclear NFB. Several
TLR4 ligands, such as oxidized LDL, hu-
man heat shock protein-60 and -70, and
peptidoglycan are found in atheroscle-
rotic plaques. They may activate NFB
and cause a release of cytokines and ma-
trix metalloproteinases. This indicates
that insulin action on TLR expression
Figure 3—PU.1 DNA binding activity to speciﬁc oligonucleotide on the TLR4 promoter following insulin dextrose and saline infusions in type 2
diabetic subjects by electromobility shift assay. A: Representative electromobility shift assay gel for PU.1 binding activity to PU-12 motif in TLR4
promoter in nuclear extracts from MNCs of type 2 diabetic subjects following 2 units/h insulin infusion. SS, supershift of PU.1–PU-12 complex from
0 h sample by a speciﬁc PU.1 antibody. B: Densitometry of PU.1 binding activity on TLR4 promoter. E, insulin; F, dextrose; Œ, saline. *P  0.05,
repeated-measures ANOVA compared with baseline; #P  0.05, two-way repeated-measures ANOVA compared with control groups.
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pression and potential prevention of
plaque rupture.
Active pharmaceutical research aim-
ing to reduce TLR4 expression to prevent
the proinﬂammatory action of LPS is cur-
rentlybeingundertaken.Thisincludesan
attempt to generate antibodies against
TLR4.TherapidsuppressionofTLR2and
TLR4 expression by insulin implies that
insulin can be used clinically in endotox-
emia and gram-negative (TLR4) and
gram-positive (TLR2) infections to limit
their inﬂammatory effects. Furthermore,
the involvement of TLR2 in ischemia-
reperfusion injury (11) and that of TLR4
inatherogenesisfurtherjustiﬁestheuseof
insulin in acute and chronic atheroscle-
rotic syndromes. In this context, the abil-
ity of insulin to suppress CRP is also
relevant, since CRP mediates injury dur-
ing ischemia-reperfusion of the heart and
synthetic small molecules (phasphotidyl
choline derivatives), which bind to and
block CRP action and reduce the size of
myocardial injury (24).
In conclusion, insulin suppresses
TLR expression and the activity of the
transcription factor PU.1. The suppres-
sive effect of insulin on TLRs also has im-
portant potential implications in the
treatment of inﬂammatory conditions in-
cluding endotoxemia, other infections,
and acute coronary syndromes in which
TLR2-related mechanisms are involved.
The suppressive effect of insulin on TLR4
is also important in understanding the re-
lationship of inﬂammation to obesity and
insulin resistance and atherosclerosis.
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